N-(1H-pyrazolo[3,4-b]pyridin-3-yl)-1-(trifluoromethyl)isoquinolin-6-amine

ID: ALA4797139

PubChem CID: 134191471

Product Number: V614811, Order Now?

Max Phase: Preclinical

Molecular Formula: C16H10F3N5

Molecular Weight: 329.29

Molecule Type: Unknown

Names and Identifiers

Canonical SMILES:  FC(F)(F)c1nccc2cc(Nc3n[nH]c4ncccc34)ccc12

Standard InChI:  InChI=1S/C16H10F3N5/c17-16(18,19)13-11-4-3-10(8-9(11)5-7-20-13)22-15-12-2-1-6-21-14(12)23-24-15/h1-8H,(H2,21,22,23,24)

Standard InChI Key:  RUEXKBWCUUFJMY-UHFFFAOYSA-N

Molfile:  

 
     RDKit          2D

 24 27  0  0  0  0  0  0  0  0999 V2000
    6.9777   -9.6370    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.9766  -10.4566    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.6846  -10.8655    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    7.6828   -9.2282    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.3915   -9.6334    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    8.3922  -10.4525    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.1008  -10.8595    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.8090  -10.4487    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.8043   -9.6266    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    9.0952   -9.2232    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    6.2686  -10.8646    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    5.5612  -10.4555    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    5.4753   -9.6448    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.6761   -9.4743    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    4.8133  -10.7893    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.2694  -10.1817    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.4733  -10.3494    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    3.2199  -11.1243    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    3.7688  -11.7317    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    4.5629  -11.5608    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.0908   -8.4060    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    9.7964   -7.9937    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    8.3810   -8.0012    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
    9.0840   -7.5858    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
  1  2  2  0
  2  3  1  0
  3  6  2  0
  5  4  2  0
  4  1  1  0
  5  6  1  0
  6  7  1  0
  7  8  2  0
  8  9  1  0
  9 10  2  0
 10  5  1  0
  2 11  1  0
 11 12  1  0
 12 13  2  0
 13 14  1  0
 14 16  1  0
 15 12  1  0
 15 16  2  0
 16 17  1  0
 17 18  2  0
 18 19  1  0
 19 20  2  0
 20 15  1  0
 10 21  1  0
 21 22  1  0
 21 23  1  0
 21 24  1  0
M  END

Alternative Forms

1. Parent:

   

   ALA4797139

   VU2957

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 329.29

Molecular Weight (Monoisotopic): 329.0888

AlogP: 4.27

#Rotatable Bonds: 2

Polar Surface Area: 66.49

Molecular Species: NEUTRAL

HBA: 4

HBD: 2

#RO5 Violations: ┄

HBA (Lipinski): 5

HBD (Lipinski): 2

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: 13.83

CX Basic pKa: 3.52

CX LogP: 3.52

CX LogD: 3.52

Aromatic Rings: 4

Heavy Atoms: 24

QED Weighted: 0.58

Np Likeness Score: -1.28

References

1. Panarese JD,Engers DW,Wu YJ,Guernon JM,Chun A,Gregro AR,Bender AM,Capstick RA,Wieting JM,Bronson JJ,Macor JE,Westphal R,Soars M,Engers JE,Felts AS,Rodriguez AL,Emmitte KA,Jones CK,Blobaum AL,Conn PJ,Niswender CM,Hopkins CR,Lindsley CW.  (2019)  The discovery of VU0652957 (VU2957, Valiglurax): SAR and DMPK challenges en route to an mGlu PAM development candidate.,  29  (2.0): [PMID:30503632] [10.1016/j.bmcl.2018.10.050]

2. Panarese JD, Engers DW, Wu YJ, Bronson JJ, Macor JE, Chun A, Rodriguez AL, Felts AS, Engers JL, Loch MT, Emmitte KA, Castelhano AL, Kates MJ, Nader MA, Jones CK, Blobaum AL, Conn PJ, Niswender CM, Hopkins CR, Lindsley CW..  (2019)  Discovery of VU2957 (Valiglurax): An mGlu₄ Positive Allosteric Modulator Evaluated as a Preclinical Candidate for the Treatment of Parkinson's Disease.,  10  (3): [PMID:30891122] [10.1021/acsmedchemlett.8b00426]

Source

Source(1):

• Scientific Literature